Frazier Life Sciences Management L.P. Sells 200,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Frazier Life Sciences Management L.P. reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 20.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 788,460 shares of the company’s stock after selling 200,000 shares during the period. Krystal Biotech makes up approximately 5.1% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 4th biggest holding. Frazier Life Sciences Management L.P.’s holdings in Krystal Biotech were worth $123,520,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Entropy Technologies LP acquired a new stake in Krystal Biotech during the 4th quarter worth about $548,000. Janney Montgomery Scott LLC grew its position in Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock worth $8,239,000 after purchasing an additional 15,545 shares during the period. Principal Financial Group Inc. grew its position in Krystal Biotech by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company’s stock worth $19,340,000 after purchasing an additional 3,727 shares during the period. abrdn plc grew its position in Krystal Biotech by 32.5% during the 4th quarter. abrdn plc now owns 57,033 shares of the company’s stock worth $8,935,000 after purchasing an additional 13,979 shares during the period. Finally, Blue Trust Inc. grew its position in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 0.6%

Shares of Krystal Biotech stock opened at $131.54 on Wednesday. The firm has a market capitalization of $3.80 billion, a PE ratio of 43.99 and a beta of 0.79. Krystal Biotech, Inc. has a twelve month low of $127.40 and a twelve month high of $219.34. The firm’s 50-day moving average price is $164.90 and its 200 day moving average price is $167.97.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million during the quarter, compared to analysts’ expectations of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup dropped their target price on Krystal Biotech from $215.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, May 16th. Guggenheim dropped their target price on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $211.13.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).